The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 319-326

  Bieniasz, Magdalena ^a   Oszajca, Katarzyna ^a   Eusebio, Mak ^a   Kordiak, Jacek ^a   Bartkowiak, Jacek ^a   Szemraj, Janusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; BMP 2; BMP 4; Lung cancer; Non small cell lung cancer; Polymorphism; Small cell lung cancer; VEGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CYTIDINE; MESSENGER RNA; THYMIDINE; VASCULOTROPIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FUNCTION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL;

AGED; AGED, 80 AND OVER; ALLELES; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350622991     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.020     Document Type: Article

References (81)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics 2008. CA Cancer J Clin 58 (2008) 71-96
2. Sun S., Schiller J.H., Spinola M., and Minnal J.D. New molecularly targeted therapies for lung cancer. JCI 117 10 (2007) 2740-2750
3. Auberger J., Loeffler-Ragg J., Wurzer W., and Wolfgang W. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr Cancer Drug Targets 6 (2006) 271-294
4. Bremnes R., Camps C., and Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51 (2006) 143-158
5. Ferrara N., Houck K., Jakeman L., and Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13 1 (1992) 18-32
6. Galligioni E., Ferro A., and Angiogenesis. Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 34 (2001) 3-7
7. Ferrara N., Gerber H.P., and LeCounter J. The biology of VEGF and its receptors. Nat Med 9 6 (2003) 669-676
8. Papaioannou A.I., Kostikas K., Kollia P., and Gourgoulianis K.I. Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. Respir Res 7 (2006) 1-13
9. Matsuyama W., Hashiguchi T., Mizoguchi A., Fumiyuki, Iwami F., Kawabata M., et al. Serum levels of vascular endothelial growth factor depends on the stage of progression lung cancer. Chest 118 (2000) 948-951
10. Voelkel N.F., Vandivier R.W., and Tuder R.M. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 290 (2006) 209-221
11. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A., Cox G., Turley H., Steward W.P., et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82 8 (2000) 1427-1432
12. Ludovini V., Gregorc V., Pistola L., Mihaylova Z., Floriani I., Darwish S., et al. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer 46 1 (2004) 77-85
13. Cheung N., Wong M.P., Yuen S.T., Leung S.Y., and Chung L.P. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 29 9 (1998) 910-914
14. Takigawa N., Segawa Y., Fujimoto N., Hotta K., and Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 18 2B (1998) 1251-1254
15. Wong M., Chan S., Fu K., Leung S., Cheung N., Yuen S., et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29 (2000) 11-22
16. Fontanini G., Boldrini L., Chine S., Pisaturo F., Basolo F., Calcinai A., et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. BJC 79 2 (1999) 363-369
17. Yuan A., Yu c, Luh K., Chen W., Lin F., Kuo S., et al. Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative reverse transcription-PCR. Lab Invest 80 11 (2000) 1671-1680
18. Ohta Y., Endo Y., Tanaka M., Shimizu J., Oda M., Hayashi Y., et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2 (1996) 1411-1416
19. Kishiro I., Kato S., Fuse D., Yoshida T., Machida S., and Kaneko N. Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology 7 2 (2002) 93-98
20. Cressey R., Wattananupong O., Lertprasertsuke N., and Vinitketkumnuen U. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer 5 128 (2005) 1-8
21. Kondo S., Asano M., Matsuo K., Ohmori I., and Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221 2 (1994) 211-214
22. Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., and Topuz E. Serum vascular endothelial growth factor (VEGF) and Bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 24 (2006) 576-580
23. Laack E., Kohler A., Kugler C., Dierlamm T., Knuffmann C., Vohwinkel G., et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13 (2002) 1550-1557
24. Suzuki M., Iizasa T., Ko E., Baba M., Saitoh Y., Shibuya K., et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 35 1 (2002) 29-34
25. Kaya A., Ciledag A., Gulbay B.E., Poyraz B.M., Celik G., Sen E., et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98 7 (2004) 632-636
26. Shimanuki Y., Takahashi K., Cui R., Hori S., Takahashi F., Miyamoto H., et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 183 1 (2005) 29-42
27. Laack E., Scheffler A., Burkholder I., Boeters I., Andritzky B., Schuch G., et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50 1 (2005) 51-58
28. Salven P., Ruotsalainen T., Mattson K., and Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79 2 (1998) 144-146
29. Niklińska W., Burzykowski T., Chyczewski L., and Nikliński J. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer 34 (2001) S59-S64
30. Brattström D., Bergqvist M., Hesselius P., Larsson A., Lamberg K., Wernlund J., et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002 37 (2002) 57-63
31. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A., Tung M.Y., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8 1 (2001) 72-79
32. Fontanini G., Vignati S., Boldrini L., Chinè S., Silvestri V., Lucchi M., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3 6 (1997) 861-865
33. Volm M., Koomägi R., and Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74 1 (1997) 64-68
34. Imoto H., Osaki T., Taga S., Ohgami A., Ichiyoshi Y., and Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115 5 (1998) 1007-1014
35. Brattström D., Bergqvist M., Larsson A., Holmertz J., Hesselius P., Rosenberg L., et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 18 2A (1998) 1123-1127
36. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 6423 (1993) 841-844
37. Skobe M., Rockwell P., Goldstein N., Vosseler S., and Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3 11 (1997) 1222-1227
38. Ilhan N., Ilhan N., and Deveci F. Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem 37 9 (2004) 840-845
39. Termaat M.F., Den Boer F.C., Bakker F.C., Patka P., and Haarman H.J. Bone morphogenetic proteins development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 87 (2005) 1367-1378
40. Ducy P., and Karsenty G. The family of bone morphogenetic proteins. Kidney Int 57 (2000) 2207-2214
41. Dimitriou R., and Giannoudis P.V. Discovery and development of BMPs. Injury Int J Care Injured 36S (2005) 28S-33S
42. Hay E., Lemonnier J., Fromigue O., and Marie P.J. Bone morphogenetic protein-2 promotes osteoblast apoptosis through a smad-independent, protein kinase C-dependent signaling pathway. J Biol Chem 276 3 (2001) 29028-29036
43. Langenfeld E.M., Bojnowski J., Perone J., and Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 80 (2005) 1028-1032
44. Raida M., Heymann A.C., Gunter C., and Niederwieser D. Role of bone morphogenetic protein 2 in the crosstalk between endothelial progenitor cells and mesenchymal stem cells and mesenchymal endothelial progenitor stem cells. Int J Mol Med 18 (2006) 735-739
45. Warburtona D., Schwarzb M., Tefftc D., Flores-Delgadoa G., Andersona K.D., and Cardoso W.V. The molecular basic of lung morphogenesis. Mech Dev 92 (2000) 55-81
46. Langenfeld E.M., and Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2 (2004) 141-149
47. Hollnagel A., Oehlmann V., Heymer J., Ruther U., and Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem 274 28 (1999) 19838-19845
48. Deckers M.L., Bezooijen R.L., Horst G., Hoogendam J., Bent C., Papapoulos S.E., et al. BMPs stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143 4 (2002) 1545-1615
49. Kozawa O., Matsuno H., and Uematsu T. Involvement of p70 S6 kinase in bone morphogenetic protein signaling: vascular endothelial growth factor synthesis by bone morphogenetic protein-4 in osteoblasts. J Cell Biochem 81 3 (2001) 430-436
50. Cunningham N.S., Paralkarp V., and Reddi A.H. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor β1 mRNA expression. Proc Natl Acad Sci 89 (1992) 11740-11744
51. White E.S., Strom S.R.B., Wys N.L., and Arenberg D.A. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol 166 (2001) 7549-7555
52. Langenfeld E.M., Calvano S.E., Abou-Nukta F., Lowry S.F., Amenta P., and Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24 9 (2003) 1445-1454
53. Shields P.G., and Harris C.C. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 18 (2000) 2309-2323
54. Mohrenweiser H.W., and Jones I.M. Variation in DNA repair is a factor in cancer susceptibility a paradigm for the promises and perils of individual and population risk estimation?. Mutat Res 400 1-2 (1998) 15-24
55. Lee S.J., Lee S.Y., Jeon H.S., Park S.H., Jang J.S., Lee G.Y., et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 14 3 (2005) 571-575
56. Chae Y.S., Kim J.G., Sohn S.K., Cho Y.Y., Moon J.H., Bae H., et al. Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology 71 (2006) 266-272
57. Watson C.J., Webb N.J.A., Bottomley M.J., and Brenchley P.C.E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12 8 (2000) 1232-1235
58. Ku K.T., Wan L., Peng H.C., Tsai M.H., Tsai C.H., and Tsai F.J. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 41 5 (2005) 497-502
59. Lin C.C., Wu H.C., Tsai F.J., Chen H.Y., and Chen W.C. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 62 2 (2003) 374-377
60. Howell W.M., Bateman A.C., Turner S.J., Collins A., and Theaker J.M. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 3 4 (2002) 229-232
61. Han S.W., Kim G.W., Seo J.S., Kim S.J., Sa K.H., Park J.Y., et al. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology 43 (2004) 1173-1177
62. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
63. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 1 (1987) 156-159
64. -ΔΔCT method. Methods 25 (2001) 402-408
65. Matsuyama K., Chiba Y., Sasaki M., Tanaka H., Muraoka R., and Tanigawa N. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 65 (1998) 1405-1409
66. Langenfeld E.M., Kong Y., and Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 25 (2006) 685-692
67. Rothhammer T., Poser I., Soncin F., Bataille F., Moser M., and Bosserhoff A. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65 2 (2005) 448-456
68. Zimmerman L.B., De Jesús-Escobar J.M., and Harland R.M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86 4 (1996) 599-606
69. Raju G.P., Dimova N., Klein P., and Huang H. SANE, a novel LEM domain protein, regulates bone morphogenetic protein signaling through interaction with smad1. J Biol Chem 278 1 (2003) 428-437
70. Buckley S., Shi W., Driscoll B., Ferrario A., Anderson K., and Warburton D. BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 286 (2004) L81-L86
71. Banks R.E., Forbes M.A., Kinsey S.E., Stanley A., Ingham E., Walters C., et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77 6 (1998) 956-964
72. Hormbrey E., Gillespie P., Turner K., Han C., Roberts A., McGrouther D., et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?. Clin Exp Metastasis 19 8 (2002) 651-663
73. Lee J.K., Hong Y.J., Han C.J., Hwang D.Y., and Hong S.I. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol 17 1 (2000) 149-152
74. Choi J., Kim H., Lim H., Nam D., Kim H., Yi J., et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung cancer 33 (2001) 171-179
75. Verheul H.M., and Pinedo H.M. Tumor growth: a putative role for platelets?. Oncologist 3 2 (1998) II znaleźć cytowania
76. Jefferson M.F., Pendleton N., Faragher E.B., Dixon G.R., Myskow M.W., and Horan M.A. 'Tumour volume' as a predictor of survival after resection of non-small-cell lung cancer (NSCLC). Br J Cancer 74 3 (1996) 456-459
77. Stevens A., Soden J., Brenchley P.E., Ralph S., and Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63 (2003) 812-816
78. Kim J.K., Oh D., Kwak S.Y., Han J.H., Chung Y.S., and Kim N.K. Genetic polymorphism of vascular endothelial growth factor (VEGF C936T) in the korean population. Korean J Biol Sci 7 (2003) 261-264
79. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., and Pilger E. A common 936 CT mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37 (2000) 443-448
80. Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C., et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106 4 (2003) 468-471
81. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 (2002) 1635-1639